Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Resistant Arterial Hypertension Cohort Study (RAHyCo)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01083017
Recruitment Status : Completed
First Posted : March 9, 2010
Last Update Posted : October 30, 2018
Sponsor:
Information provided by (Responsible Party):
Georg EHRET, University Hospital, Geneva

Brief Summary:
The purpose of this study is to investigate the epidemiology of resistant hypertension, evaluate the efficacy and feasibility of a standardized drug treatment regimen (including the randomization of two doses of the diuretic used - chlorthalidone), study two interventions in the group of patients that is non-compliant, and study environmental and genetic variables of individuals with resistant hypertension in a family design.

Condition or disease Intervention/treatment
Hypertension Essential Hypertension Resistant Hypertension Drug: chlorthalidone Behavioral: motivational intervention for non-compliant individuals Drug: standardized anti-hypertensive treatment

Layout table for study information
Study Type : Observational
Actual Enrollment : 74 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Interventional Prospective Cohort Study, Multi-center With Nested Case-control Studies (Family-based and Non-family Based) on Individuals With Resistant Arterial Hypertension.
Study Start Date : April 2011
Actual Primary Completion Date : May 2017
Actual Study Completion Date : May 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
chlorthalidone Drug: chlorthalidone
chlorthalidone 25mg/d vs. chlorthalidone 50mg/d

motivational invervention
motivational interview(s) vs. repeated calls vs. no particular intervention
Behavioral: motivational intervention for non-compliant individuals
motivational interview(s) vs. repeated calls vs. no particular intervention

standardized anti-hypertensive treatment Drug: standardized anti-hypertensive treatment
olmesartan, amlodipine, chlorthalidone, +- spironolactone




Primary Outcome Measures :
  1. blood pressure control [ Time Frame: at 12 weeks after initiation of standard treatment ]

Secondary Outcome Measures :
  1. cardiovascular morbidity and mortality [ Time Frame: 5 years ]
    additional secondary: BP control at yearly follow-up


Biospecimen Retention:   Samples With DNA
serum, DNA, urine


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients addressed to a speciality consultation at Geneva University Hospital
Criteria

Inclusion Criteria:

  • informed consent
  • resistant hypertension at the moment of inclusion
  • 18 years or more, both sexes are included
  • women at reproductive age: consenting to use oral contraception

Exclusion Criteria:

  • patients mentally impaired or unable to give informed consent
  • patients speaking only a foreign language other than French, German, or English
  • patients living far away, making the study visits not practical

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01083017


Locations
Layout table for location information
Switzerland
Geneva University Hospitals
Geneva, Switzerland
Lausanne University Hospital, CHUV
Lausanne, Switzerland
Kantonsspital Luzern
Luzern, Switzerland
Sponsors and Collaborators
University Hospital, Geneva
Investigators
Layout table for investigator information
Principal Investigator: Antoinette PECHERE, MD Geneva University Hospitals, Switzerland
Principal Investigator: Georg B EHRET, MD Geneva University Hospitals, Switzerland
Layout table for additonal information
Responsible Party: Georg EHRET, intern, University Hospital, Geneva
ClinicalTrials.gov Identifier: NCT01083017    
Other Study ID Numbers: RAHyCOstudy
33CM30‐124087 ( Other Grant/Funding Number: Swiss National Science Foundation )
CER09-237 ( Other Identifier: IRB )
First Posted: March 9, 2010    Key Record Dates
Last Update Posted: October 30, 2018
Last Verified: October 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Essential Hypertension
Vascular Diseases
Cardiovascular Diseases
Chlorthalidone
Antihypertensive Agents
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action